Bio-Gene TechnologyASX:BGT Gross Margin % is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 736 Biotechnology companies, Bio-Gene Technology ranks worse than 135869.43% on this metric.
The historical rank and industry rank for Bio-Gene Technology's Gross Margin % or its related term are showing as below:
ASX:BGT's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Bio-Gene Technology had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Bio-Gene Technology was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bio-Gene Technology had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bio-Gene Technology Gross Margin % Related Terms
Bio-Gene Technology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Gene Technology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BGT vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Bio-Gene Technology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bio-Gene Technology (ASX:BGT) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio-Gene Technology and its competitors. According to the industry distribution chart, Bio-Gene Technology ranks #999999 out of 736 companies in the Biotechnology industry.
Is Bio-Gene Technology's Gross Margin % too high?
Bio-Gene Technology's current Gross Margin % is 0.00%. Based on the distribution chart, Bio-Gene Technology ranks #999999 out of 736 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Gene Technology's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #999999 out of 736 companies for Gross Margin %. This places Bio-Gene Technology in the lower half of its industry. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio-Gene Technology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gene Technology's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 